Showing results (3171-3180 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|October 23, 2008
Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studiesTushar S Basu Baul, Smita Basu, Dick de Vos, et al.
Investigational New Drugs|August 11, 2020
Analysis and identification of novel biomarkers involved in neuroblastoma via integrated bioinformaticsBo Chen, Peng Ding, Zhongyan Hua, et al.
Investigational New Drugs|August 11, 2020
Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumorsXingxing Yuan, Zujun Sun, Qingyun Yuan, et al.
Investigational New Drugs|August 13, 2020
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapyHidenobu Ishii, Koichi Azuma, Akihiko Kawahara, et al.
Investigational New Drugs|August 25, 2020
Effects of zinc porphyrin and zinc phthalocyanine derivatives in photodynamic anticancer therapy under different partial pressures of oxygen in vitroMartin Pola, Hana Kolarova, Jiri Ruzicka, et al.
Investigational New Drugs|April 19, 2023
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumorsArvind Dasari, Erika P Hamilton, Gerald S Falchook, et al.
Investigational New Drugs|April 5, 2023
Mesenchymal stem cells: a trojan horse to treat glioblastomaAntoine Chartouni, Antoine Mouawad, Marc Boutros, et al.
Investigational New Drugs|March 28, 2021
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrationsSarina A Piha-Paul, Analía Azaro, Hendrik Tobias Arkenau, et al.
Investigational New Drugs|July 10, 2020
Hydroxyethylcellulose as a methotrexate carrier in anticancer therapyJarosław Ciekot, Mateusz Psurski, Katarzyna Jurec, et al.
Investigational New Drugs|February 17, 2015
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumorsPatricia M LoRusso, Priscila H Goncalves, Lindsay Casetta, et al.
Pageof 372